Back to Search Start Over

Sustained Effectiveness of Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A 48-Week Real-World Study.

Authors :
Hagino, Teppei
Hamada, Risa
Yoshida, Mai
Saeki, Hidehisa
Fujimoto, Eita
Kanda, Naoko
Source :
Pharmaceuticals (14248247). Apr2024, Vol. 17 Issue 4, p519. 11p.
Publication Year :
2024

Abstract

Clinical trials and real-world studies have shown the effectiveness of upadacitinib for treating rash and pruritus in patients with atopic dermatitis (AD). This study aimed to determine whether the early reduction in rash or pruritus at week 12 of upadacitinib treatment could be maintained at later treatment stages. This retrospective study involved 227 and 73 patients with moderate-to-severe AD treated with 15 and 30 mg upadacitinib daily, respectively. The eczema area and severity index (EASI) scores, peak pruritus numerical rating scale (PP-NRS), and investigator's global assessment (IGA) were analyzed. At week 12, patients were divided into achievers and non-achievers of EASI 75, 90, 100, absolute EASI ≤ 2, IGA0/1, PP-NRS4, or absolute PP-NRS ≤ 1. Achievement rates for each endpoint were assessed at later time points (weeks 24, 36, and 48) in both groups. Week 12 achievers largely maintained their endpoint achievements until week 48, regardless of dosage (15 mg or 30 mg). Week 12 non-achievers saw an increasing achievement rate of EASI 75 until week 48. The initial reduction in rash and pruritus at week 12 persisted until week 48 with upadacitinib treatment, suggesting potential benefits for patients requiring prolonged treatment despite not achieving EASI 75 at week 12. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
14248247
Volume :
17
Issue :
4
Database :
Academic Search Index
Journal :
Pharmaceuticals (14248247)
Publication Type :
Academic Journal
Accession number :
176905663
Full Text :
https://doi.org/10.3390/ph17040519